Stay updated on Phase 2 NSCLC Platform Study Post-Osimertinib Clinical Trial
Sign up to get notified when there's something new on the Phase 2 NSCLC Platform Study Post-Osimertinib Clinical Trial page.

Latest updates to the Phase 2 NSCLC Platform Study Post-Osimertinib Clinical Trial page
- Check3 days agoChange DetectedAdded a site-wide notice about government funding lapse and NIH Clinical Center status. Updated the revision tag from v3.4.0 to v3.4.1.SummaryDifference0.4%

- Check10 days agoChange DetectedThe history page now includes a glossary display option and color-coded legends for additions and deletions, and revision notes have been updated from v3.3.4 to v3.4.0; To avoid being alerted by small changes, set an alert condition by clicking below.SummaryDifference0.5%

- Check17 days agoNo Change Detected
- Check25 days agoChange DetectedThe record history now shows a new revision entry (v3.3.4) and the previous revision (v3.3.3) was removed. To avoid being alerted by small changes, set an alert condition by clicking below.SummaryDifference0.1%

- Check46 days agoChange DetectedA new revision entry 'Revision: v3.3.3' was added to the Record History, and the 'HHS Vulnerability Disclosure' item and the older 'Revision: v3.3.2' entry were removed. To avoid being alerted by small changes, set an alert condition by clicking below.SummaryDifference0.1%

- Check75 days agoChange DetectedAdded Revision: v3.3.2 to the history and removed Revision: v3.2.0. This represents a minor UI/version update to the page.SummaryDifference0.1%

- Check82 days agoChange DetectedRemoved the banner warning about government funding lapses and processing delays that previously appeared on the page. To avoid being alerted by small changes, set an alert condition by clicking below.SummaryDifference0.4%

Stay in the know with updates to Phase 2 NSCLC Platform Study Post-Osimertinib Clinical Trial
Enter your email address, and we'll notify you when there's something new on the Phase 2 NSCLC Platform Study Post-Osimertinib Clinical Trial page.